skip to Main Content

Pant Pushes for De-Escalated Options, Targeted Therapy in Pancreatic Cancer

Pant Pushes for De-Escalated Options, Targeted Therapy in Pancreatic Cancer
Chemotherapy has been a mainstay in advanced pancreatic cancer, but it can be challenging for patients to tolerate, according to Shubham Pant, MD, who added that de-escalated maintenance approaches could be one way to help patients preserve their quantity and quality of life.

For example, data from the phase II PRODIGE 35-PANOPTIMOX trial showed comparable overall survival (OS) among previously untreated patients with advanced disease who received 6 months of FOLFIRINOX versus 4 months of FOLFIRINOX followed by 5-fluorouracil/leucovorin (LV5FU2).  Read more . . . 


Back To Top